Current management of castrate-resistant prostate cancer.
about
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerResponse to degarelix after resistance to leuprolide in a patient with metastatic prostate cancerMechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancerCombination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor GrowthSkeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trialsAndrogen receptor as a driver of therapeutic resistance in advanced prostate cancer.Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect ComparisonA phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.Clinical management and burden of prostate cancer: a Markov Monte Carlo model.A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.The effects of 1,4-dimethylpyridine in metastatic prostate cancer in miceSurvival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Current treatment strategies for castration-resistant prostate cancerTargeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings.Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling.Ca2+ Selective Host Rotaxane Is Highly Toxic Against Prostate Cancer Cells.Differential role of PTEN in transforming growth factor β (TGF-β) effects on proliferation and migration in prostate cancer cells.The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University HospitalsSynthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer.PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells.PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cellsCaveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer
P2860
Q26744431-34BAB936-2E92-4FF0-86EB-5293F752BD2FQ27022516-4D070018-1679-4479-91E5-AF84523D8F3CQ27024795-49DED4AF-D39A-490B-8ACF-299A347EB0D5Q28547500-54D9156A-5042-41AD-9DE1-55A83D441A00Q31152383-88D0781F-33AA-49D2-BA29-B84443E25879Q33775723-545530D2-53E6-4B8F-8DAC-F48FE38EC7B2Q34412589-4CF76257-81E4-4984-8FBA-5E8EC8E820CCQ34520021-573B0E9F-9CDE-4A38-B1B6-4CDB236CA8C5Q34634410-D24741F6-EA9D-4376-926E-8B21C5413AF8Q35009235-31E848F1-820E-49A5-9B2A-C173C3CB94D1Q35130059-B4DFDD39-0B9A-4382-95DA-EDFA5B693F1EQ36300102-4BA290ED-4FDC-43F9-9B21-081FAC5FA1B8Q37124741-C4F530C2-8578-4FAE-8120-211D5EC04940Q37709535-8B6EBAC1-E1A4-4197-940F-0C2969146AB9Q37860950-C0734173-D3F0-4BE1-B946-626A19FF9E4EQ38508313-19A8D06D-CCE7-445A-BD00-E1FC931A3325Q39037597-1F40CE33-8E2A-4FCD-8A74-E0AB8D83EA1BQ39174720-F3BF822E-7FE8-4CCA-B728-AC84CE0672E4Q41600644-271E971B-BEF1-4AC1-883F-A47E86E21257Q41906245-F533D35F-46A0-42C0-9904-DA3FEA056794Q42203821-F2EEC791-23EA-4FAA-B6E5-FE1DA5B06701Q42713706-40A276A2-3240-41BF-BC48-110D5C0C49FFQ47969307-2BFA05A6-039C-4869-A04E-88D46664E3B5Q48229042-955DE27B-DF27-49B4-95E2-B5EFCAF4BE3DQ49649039-A7C63561-F645-4450-9C78-B44169C01C4AQ52571246-5DA1D8B4-7A82-4EFE-98FC-D1E7518F035DQ52639519-830104D0-7B1E-407A-9A22-2767D5B9BF8CQ57175832-5C90B4E5-B64F-4CBA-A526-42696576B27FQ57484740-129AC9E1-2356-432F-A951-3EB1AD3E973C
P2860
Current management of castrate-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Current management of castrate-resistant prostate cancer.
@ast
Current management of castrate-resistant prostate cancer.
@en
Current management of castrate-resistant prostate cancer.
@nl
type
label
Current management of castrate-resistant prostate cancer.
@ast
Current management of castrate-resistant prostate cancer.
@en
Current management of castrate-resistant prostate cancer.
@nl
prefLabel
Current management of castrate-resistant prostate cancer.
@ast
Current management of castrate-resistant prostate cancer.
@en
Current management of castrate-resistant prostate cancer.
@nl
P2860
P356
P1433
P1476
Current management of castrate-resistant prostate cancer
@en
P2093
P2860
P356
10.3747/CO.V17I0.718
P478
17 Suppl 2
P577
2010-09-01T00:00:00Z